cas 915087-25-1|| where to buy 4-Amino-2-fluoro-N-methylbenzamide

Nom du produit:4-Amino-2-fluoro-N-methylbenzamide

IUPAC Name:4-amino-2-fluoro-N-methylbenzamide

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM255748-500g	in stock	ưźĽ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 915087-25-1 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:915087-25-1; Formule moléculaire:C8H9FN2O; Point de fusion:-; Code SMILES:O=C(NC)C1=CC=C(N)C=C1F; Densité:

: Numéro de catalogue:CM255748; Poids moléculaire:168.17; Point d'ébullition:320°C at 760 mmHg; N° Mdl:MFCD09909322; Stockage:Keep in a tight container and store at ambient temperature

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Enzalutamide; Aug. 23, 2023, FDA grants priority review for XTANDI(enzalutamide) in non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
XTANDI (enzalutamide) is an androgen receptor signaling inhibitor. Androgen receptor inhibitors interfere with the connection between androgens and androgen receptors. This can help slow cancer cell growth.XTANDI is currently approved for one or more of these indications in more than 100 countries, including in the U.S., European Union and Japan. Over one million patients have been treated with XTANDI globally.